Lille, September 19

4P-Pharma, a biotechnology company specializing in the development of new medicines in the areas of cancer, inflammatory diseases, and stimulants abuse, announces the entry into its capital of M comme Mutuelle. This new funding will help support the first phase I clinical trial led by 4P-Pharma.





Read the full press release :

EN: Press Release 4P-Pharma and M comme Mutuelle 2016

FR: Communiqué de presse 4P Pharma-M comme Mutuelle 2016


Press contact M comme Mutuelle

Ghislain Fauquet, director of communication

E-Mail :  . Phone : 33 (0) 6 48 77 12 04 .


Press contact 4P-Pharma

Keren Bismuth, scientific communications manager.

E-mail: Phone :33 (0)9 72 84 72 64.